Nivolumab associated myasthenia gravis with severly elevated cardiac biomarkers: to treat or not to treat?

29 June 2021 (08:33 - 08:45)
Organised by:
Congress Presentation Part of: Clinical Case Award Cardio-Oncology HFA Premium Access Heart Failure 2021

ESC 365 is supported by

ESC 365 is supported by